Objectives -To describe age specific frequencies of Pap smear and colposcopy use in the Australian Capital Territory (ACT) and to estimate the cumulative effects of current patterns of use. Setting -Frequencies of Pap smear and colposcopy use were estimated for the financial year from 1 July 1989 to 30 June 1990. Eligible women were between the ages of 15 and 74, living in the ACT. Methods -Data collected from a 10% sample of subjects enrolled with Medicare and from the only public pathology laboratory in the ACT were used to estimate age specific frequencies. The expected number of deaths from cervical cancer in the ACT in the absence of a screening programme was estimated by applying Australian age specific mortality rates for cervical cancer between 1960 and 1964 to the 1989 ACT population.
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A life table approach was used to simulate the cumulative risk of colposcopy -given current age specific rates -on a hypothetical cohort of 1000, 15 year old women.
Results -Forty four per cent (95% confidence interval (CI) 42·9 to 44·9) ofwomen had a Pap smear and 2·5% had colposcopy (95% CI 2·4 to 2·6). Two and a half per cent of 15 to 24 year old women had colposcopy (95% CI 1·9 to 3·1). The ratio of women having Pap smears to women having colposcopy was 17·8:1 (95% CI 17·7 to 17·9). An estimated 247 women had colposcopy for every cervical cancer death; in the 15 to 24 year old age group this ratio was 47900:1. A 15 year old woman exposed to current rates of colposcopy (adjusted for hysterectomy) has a 76·8% chance of having a colposcopy during her life time. Conclusions -Many more women will have colposcopy than will develop cervical cancer, which undermines the cost effectiveness of Australia's cervical cancer screening programme. For a cervical cancer screening programme to be effective it must have high programme sensitivity and specificity -that is, it must identify most of the women in the at-risk population who would develop cervical cancer in the absence of a screening programme and distinguish these women, as accurately as pos-sible, from the women who would not develop cervical cancer. To do this, the programme has to identify most women who have preclinical disease. Morrison defined preclinical disease as a condition that is undiagnosed at the time of screening, which would progress over time into a more serious form of the disease. 1
In the case of cervical cancer screening, women are deemed to have preclinical disease if they have cervical abnormalities that would develop over time into cervical cancer. Cervical intraepithelial neoplasia (CIN) has generally been considered to be preclinical disease. Although recent studies have shown that most women with CIN I or CIN II do not develop CIN III or worse in many years of follow Up,2-6 it is impossible to know whether an individual woman with cervical intraepithelial neoplasia will develop cervical cancer.
What of human papillomavirus infection? It is now accepted that such infection is probably causally related to cervical cancer." Yet the prevalence of high risk types of human papillomavirus infection (found by tests that detect human papillomavirus DNA) is considerable, even when women have normal cytology.t" Syrjanen et at estimated that 79% of Finnish women will have a cytology report indicating human papillomavirus during their lifetime . 11 And what about women who have abnormalities such as mild atypia? Some authors have expressed concern that a significant proportion of these women have cervical intraepithelial neoplasia and recommended that women with mild atypia should be referred for colposcopy and biopsy. [12] [13] [14] [15] [16] There are many uncertainties about the significance of different cervical abnormalities and confusion about the most appropriate approach for women who have Pap smear reports of CIN I, human papillomavirus, atypia, or even inflammation. Recent Australian studies have shown that most women with CIN II or CIN III are referred for colposcopy," while 50% of women with CIN I, and 19% of women with mild atypia, have colposcopy." Only recently have clinical guidelines for the care of women with screen detected abnormalities been published in Australia." Table 1 summarises this national screening policy.
If we are to evaluate the likely long term cost effectiveness of Australia's cervical cancer screening programme, we require further information about current patterns of colposcopy use and estimates of the cumulative effect of current patterns of use. This paper presents data collected from the Australian Capital Territory. The age specific frequencies of Pap smear and colposcopy use are described and 
Guidelines for evaluation
Colposcopic assessment and directed biopsy. Definitive treatment when lesion confirmed Refer to gynaecologist with expertise in the colposcopic evaluation of suspected malignancies or to a special unit Refer to gynaecologist skilled in the management of gynaecological malignancies or a specialist unit for urgent evaluation and definitive management Refer for further investigation by colposcopy and possible biopsy unless there is an obvious reason for the diagnostic difficulty that can be readily corrected Repeat cervical smear at 12 month intervals until the smear returns to normal Repeat the cervical smear at six months. If HPV' effect persists, repeat the smear in a further six months. If the HPV change is persistent at 12 months, colposcopy is recommended with directed biopsy if indicated Repeat the cervical smear in six months using both cytobrush and spatula. If after six months the cervical smear still indicates a low grade abnormality, the woman should be referred to a gynaecologist Refer for colposcopy and, if indicated, biopsy. If CIN I is confirmed on biopsy then the woman should be offered the option of treatment or follow up with six monthly Pap smears until two smears are negative Six monthly smears until two are negative, then annual smears for two years and then biennial smears
Repeat smears every two years
Routine biennial smears provided no symptoms or history suggestive of cervical pathology. Start screening between ages 18 and 20 or within one to two years of first sexual intercourse, whichever is the later. Women may discontinue smears at age 70 provided they have had two negative smears in the past five years the cumulative effect of current patterns of referral for colposcopy simulated.
Methods

FREQUENCIES OF PAP SMEAR AND
COLPOSCOPY USE
The number of women in each age group (15-24, 25-34, 35--44, 45-54, 55-64, older than 65) who had a Pap smear or colposcopy between 1 July 1989 and 30 June 1990 was estimated from Medicare statistics and public laboratory data.
Medicare is Australia's system of universal health insurance. Services provided in the private sector are charged for on a fee for service basis and rebated by the federal government. Item numbers are used to describe the different services and a scheduled fee is set for each item number.
In the Australian Capital Territory most cervical cytology is evaluated in private laboratories. The public laboratory is funded through a public hospital grant and does not receive a Medicare rebate. The 10% file of subjects enrolled with Medicare was used to estimate the number of women in each age group who claimed through Medicare for a Pap smear in the financial year 1989-90 (1 July 1989 to 30 June 1990). The public laboratory collects statistics on the number of women having smears in each age group. (As the public laboratory provided data by calendar year, its totals for 1989 and 1990 were averaged to provide an estimate of the number of Pap smears by age group for the financial year 1989-90.) The Medicare estimates were multiplied by 10 and added to the public laboratory totals to estimate the number of women having Pap smears in each age group.
At the time of the study there was no public outpatient colposcopy service in the Australian Capital Territory. Therefore, the 10% Medicare sample was used to estimate the annual age specific frequencies of women having colposcopy.
Because the Australian Capital Territory Pap smear campaign provided educational, promotional, and clinical services over the time the data were collected, the frequencies of Pap smear and colposcopy use might be higher than would ordinarily occur. Since this study, however, claims for colposcopy have increased more than claims for Pap smears.
The denominators used to calculate the frequencies were the number of subjects enrolled with Medicare in the relevant age group for the financial year 1989-90 after the adjustment for the estimated hysterectomy rate in each group.:" HYSTERECTOMY ESTIMATES Cervical cancer screening is unnecessary for women who have had a hysterectomy unless the hysterectomy was done because of cervical neoplasia, or its precursors, or the hysterectomy was subtotal (the cervix was not removed);" As most women who have a hysterectomy are thereby removed from the risk of subsequent colposcopy, they should not be included in the denominator for Pap smear and colposcopy rates.
The Australian National Health Survey, conducted in June 1989, was used to estimate the proportion of women in different age groups who had had a hysterectomy. Because the Medicare data for colposcopies and Pap smears were collected during 1989-90, the age specific frequencies of hysterectomy and the Medicare data were derived from women from similar birth cohorts. To adjust for hysterectomy the denominators were multiplied by one minus the estimated proportion of women in each age group who had undergone hysterectomy.
AGE SPECIFIC PATTERNS OF FOLLOW UP
Age specific ratios of women having smears to women having colposcopy were estimated from th~Medicare and public laboratory data. Ninety five per cent confidence intervals were calculated using the method described by Cochran." AGE SPECIFIC RATIOS OF COLPOSCOPY TO EXPECTED NUMBER OF DEATHS FROM CERVICAL CANCER Most Australian states started screening in 1965. We calculated the Australian age specific mortality rates for cervical cancer between 1960 a~d 1964 i~clusive. These rates were then apphed to subjects enrolled with Medicare in the relevant age groups" to estimate the expected number of cases of cervical cancer in the absence of a screening programme. In 1993, 99·1 % .of the Australian Capital Territory population were enrolled in Medicare.
CURRENT AND PREDICTED TRENDS IN COLPOSCOPY USE
The number ofwomen claiming for colposcopy between 1 January 1989 and 30 April 1990 was obtained from the 10% Medicare file. Women who had claimed for colposcopy in the previous two years were excluded. Therefore, women included in this sample were assumed to be women claiming for a new episode of colposcopy. Because the data were obtained from 10% of the population over a 16 month period (for administrative convenience), this number was multiplied by 7·5 (10 x 12/16) to provide an estimate of the number of women claiming for colposcopy in a 12 month period.
After estimating the number of women iñ ac~age group claiming for colposcopy the incidence rates and cumulative risk of colposcopy were calculated, using a life table approach. This is detailed below.
The terms used in the life table are:
nMx= No of colposcopies for women aged between x and x +n Midyear population of women between the ages x and x +n nCx=No of women who have never previously had a colposcopy who have a colposcopy between ages x and x + n l, = No of women who have not had a colposcopy by age x lx+n=No of women who have not had a colposcopy by age x + n nmx = rate of colposcopy among women at risk of having their first colposcopy. nCx is estimated from the Medicare sample collected over the 16 month period, and assumes that all women in the sample are claiming for their first colposcopy. Therefore, 31 M =nCx n x nWx where nWx is given by the number of women enrolled in Medicare on 30 June 1989 between ages x and x+n. However, nMx does not equate to nm, from a conventional life table. In a conventional life table nmx refers to the rate of an event, usually death, between ages x and x + n. Death removes people from population counts, but nWx includes all women whether or not they have had a previous colposcopy. Therefore W will .
s n x include women who are not at risk of a first colposcopy. Hence one cannot use the con-ve~~i?nal method that converts rates to probabilities to derive Ix. The term l, can be derived with knowledge of nM., however. The value of 1 is calculated using the method described by Dickinson and Hill. 23 Details of the derivation are outlined in Appendix 1. Briefly, the method enables us to calculate lx+n after women who have had previous colposcopy have been removed from the denominator of nmx. With this method it can be shown that lx+n = l, -n x nMx x 1 0, where 10=No of women who have not had a colposcopy at exact age 0, or who have not had a colposcopy at the beginning of the simulation. This approach enables us to simulate the experience of future cohorts of women if colposcopy rates remained the same.
If one assumes that women who have had a hysterectomy are no longer at risk of colposcopy the denominator for colposcopy rates should be adjusted to include only women who have not had a hysterectomy between ages x and x + n. To adjust for hysterectomy, nW x has been multiplied by the proportion ofwomen between ages x and x + n who have not had a hysterectomy, before adjusting for colposcopy. The cumulative risk of colposcopy is also shown after adjusting for hysterectomy. Table 2 shows the Australian National Health Survey estimates of the proportion of women in various age groups who had had a hysterectomy. Table 3 details the proportions of women of different ages who had Pap smears and colposcopies in the Australian Capital Territory in the financial year 1989~90. Women between t The standard errors for these estimates were calculated using the method descnbed in reference 24, appendix C: 48-9. For women between the ages 15 and 54 and 55 and 74 the proportion of women who had undergone hysterectomy between the ages of 18 and 24 and 55 and 64 have been used. the ages of 25 and 54 had the highest rates of Pap smear and colposcopy use. Overall, in 1989-90, 44% of women in the Australian Capital Territory had a Pap smear and approximately one in 40 had a colposcopy. Table 3 also shows the age specific ratios of women having smears to women having colposcopy and the age specific ratios ofwomen having colposcopy to the expected number of women who would die from cervical cancer without screening. On average, 18 women had Pap smears for every woman who had a colposcopy. Overall, it is estimated that 247 women had colposcopy for every cervical cancer death. Table 4 shows the life table probabilities for colposcopy by ages 25, 35, 45, 55, and 75 with and without adjustment for hysterectomy. Whether or not an adjustment for hysterectomy is made, if current cross sectional rates of colposcopy continue, and current screening participation rates are maintained, most 15 year old women will have at least one colposcopy by age 75.
Results
Discussion
There is a disparity between risk of cervical cancer and use of cervical cancer screening and colposcopy services. The mismatch is greatest for younger women. Although women younger than 35 have much lower rates of cervical cancer than women over 35, their patterns of colposcopy use are similar to those of women aged between 35 and 54, and higher than those of women over 55. Differences in colposcopy use by age may be explained by age specific differences in the rates of cytological abnormalities, differential rates of referral for colposcopy after Pap smear, different intensities of follow up (that is, it is possible that younger women are followed up for longer, increasing the frequency of colposcopy use in the younger age groups), and higher frequency ofPap smear use in the younger age groups so that transient abnormalities are more likely to be detected.
Although both Medicare and the public sector laboratory can each provide figures on the total number of women having a Pap smear, rather than just the total number of Pap smears taken, it is possible that a woman may have had more than one Pap smear which were processed by both a public and private laboratory. In such instances, women would be counted twice in the numerator of Pap smear frequencies resulting in an overestimate of Pap smear frequency. However, the public laboratory only processes 15% of the smears taken in the Australian Capital Territory and therefore it is unlikely that double counting will seriously bias the results. There is another possible source of bias from using public laboratory data; this laboratory may process cytology samples from some women outside the Australian Capital Territory. Including these women in the estimation of Pap smear frequency will also lead to an overestimate of the frequency of Pap smear use.
In our life table simulation of cumulative risk of colposcopy, after excluding women who had a colposcopy more than two years previously, we assumed that the women claiming through Medicare for colposcopy were claiming for their first colposcopy. Probably, however, we included women who had colposcopy more than two years ago owing to a previous abnormality. Inclusion of these women will inflate estimates of incidence because women who have had a previous abnormality are at greater risk of another abnormality than other women. 25 Even if the age specific incidences for colposcopy are inflated by 50%, however, the cumulative risk ofcolposcopy is 38% at age 75, after adjustment for hysterectomy. A clear mismatch between risk of colposcopy and risk of cervical cancer is still evident.
The life table simulation includes all women. If a woman does not participate in screening she is not at risk of colposcopy. However, in the 1989 National Health Survey, 71 % of women between ages 18 and 64 reported having a Pap smear in the previous three years; 77% of Australian women reported having a smear in the previous five years." The survey did not differentiate between Pap smears taken for the investigation of symptoms and routine smears. The Pap smear frequencies are likely to be inaccurate because women who had a hysterectomy were not excluded and Pap smear frequencies based on self reporting are likely to be overestimates." If it were possible to adjust the denominator to include only women who participate in screening (such as through the employment of a microsimulation model), the cumulative risk estimates for these women would be greater at the ages shown.
Age specific ratios of women having smears to women having colposcopy gives information about the likelihood of a woman in a particular age group having a colposcopy if she has a Pap smear. Women aged 15 to 54 seem to have more intensive follow up. If they participate in screening they are more likely to have colposcopy than women older than 55 (see table  3 ). Possibly, women over 55 are previously well screened and hence have a lower risk of abnormalities than other women. Interestingly, women aged 45 to 54 have more intensive follow up than women in the 35 to 44 year old age group and similar patterns to those of women aged 15 to 34. It is possible that many women in the 45 to 54 year old age group are perimenopausal and are experiencing irregular bleeding. The irregular bleeding, which is in most situations probably due to hormonal changes, might be investigated by colposcopy to exclude a cervical malignancy.
Almost 50 000 women aged 15 to 24 would have colposcopy for every one woman who would die of the disease (see table 3 ). This ratio decreases with age. To estimate these ratios we have assumed that the age specific mortality rates for cervical cancer have not changed in the past 20 years. In the youngest women the ratio is so large that it is unlikely that changes in the age specific mortality rates could account for the mismatch between the risk of colposcopy and risk of death.
The implications of current practices are significant. If cross sectional rates for colposcopy continue it is estimated that 77% of 15 year old women will have colposcopy by age 75. In contrast, it is estimated that a woman in a Western country that does not have a cervical cancer screening programme has a 1·6% risk of developing squamous cell cervical cancer in her lifetime."
The mismatch between risk of cervical cancer and risk of colposcopy may be a consequence of the different perspectives of public health practitioners and clinicians. The clinician cannot know whether a woman they see with a cytological abnormality will develop cervical cancer in the future. Previous research has shown that when clinicians are faced with uncertainty they perform diagnostic tests to assure 33 their patients and thernselves.Y" Fear of litigation also drives clinicians to perform more diagnostic procedures. 30 In the case of cervical cancer screening, however, the clinical aim for diagnostic certainty results in many more women being investigated for the precursors of cervical cancer than would ever develop cervical cancer. The Australian guidelines for the clinical care of women with cervical abnormalities were developed after this study was conducted. 19 It is possible that these guidelines will reduce the high frequency of colposcopy by reducing the frequency with which clinicians refer women for colposcopy. However, previous research has shown that protocols alone do not always change clinical practice." Also, recommendations for the clinical care of women with low grade abnormalities (CIN I or less) are conservative. Colposcopy rates could also be decreased by increasing the screening interval from two to three years or by increasing the age at which women start screening to 25.
Investigating a large number of women, as we are now, may increase the sensitivity of the screening programme, but the trade off is a substantial reduction in programme specificity. Colposcopy will become the norm, the Pap smear will become an inefficient screening test, and the goal of a cervical cancer population based screening programme -to achieve a cost effective reduction in cervical cancer incidence and mortality -will not be met. The high rates of investigation with colposcopy will be expensive for the community, and women will also incur significant personal and financial costs.
